Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study.

IF 20.1 1区医学 Q1 ONCOLOGY

Cancer Communications Pub Date : 2024-10-10 DOI:10.1002/cac2.12611

Ziyan Tong, Ning Zhu, Hong Shen, Ying Yuan

引用次数: 0

查看原文本刊更多论文

针对无法切除的 III 期表皮生长因子受体突变 NSCLC 的靶向疗法创新取得令人振奋的进展：III 期 LAURA 研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

25.50

自引率

4.30%

发文量

153

审稿时长

4 weeks

期刊介绍： Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.